Phase II study of gefitinib combined with carboplatin/pemetrexed for elderly patients with EGFR mutated advanced non-small cell lung cancer
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000016391
- Lead Sponsor
- Tohoku University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Not provided
1) Radiographically confirmed interstitial pneumonitis or pulmonary fibrosis. 2) NSCLC harboring T790M mutation 3) No prior gefitinib or pemetrexed treatment as ajuvant/neoajuvant therapy. 4) Symptomatic brain metastases 5) Radiation therapy for primary site. 6) Severe concurrent disease 7) HBs antigen or HBc antibody or HBs antibody positive 8) Patient are treated with steroid continuously 9) Pleural and peritoneal effusion likely to require surgical intervention, or pericardial effusion 10) Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy. 11) Active double cancer 12) Physician concludes that the patient's participation in this trial is inappropriate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method